OncoEthix In-Licenses anticancer compound

Please login or
register
18.06.2012

OncoEthix, a Swiss-based company specializing in oncology drug development, has in-licensed a compound, OTX015, from Mitsubishi Tanabe Pharma Corporation. Studies have shown that the compound is active across a wide range of hematologic malignancies.

Mitsubishi Tanabe Pharma Corporation had successfully completed Phase 1 clinical studies in healthy volunteers and licensed the compound to OncoEthix to take advantage of its expertise in the development of novel oncology drugs. OncoEthix plans to initiate clinical trials later this year.

Dr Esteban Cvitkovic, Chief Scientific Officer of OncoEthix, noted that "the studies that we performed have confirmed that OTX015 is active across a wide range of hematologic malignancies. I look forward to exploring the compound's potential in the clinic."

Dr Kay Noel, Chief Operating Officer who led the licensing effort with Bertrand Damour, Chief Executive Officer, said: "We are excited about the opportunity to lead the exploration of one of the most promising new cancer targets."

OncoEthix is a privately held biotechnology company based in Lausanne that plans to develop a small portfolio of oncology drug candidates, ensuring a proper foundation for commercial success. The company's lead product, OTX008, a synthetic small molecule targeted to galectin-1, entered Phase 1 clinical trial in the first quarter of 2012. OncoEthix was incorporated in 2007 and completed a Series A financing round led by Index Ventures and Endeavour Vision in August 2009.

0Comments

More news about

OncoEthix GmbH

Company profiles on startup.ch

OncoEthix GmbH

rss